- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06274541
Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study
Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer: The t-BRCA Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This pilot study will evaluate the feasibility of a NGS-based tumour BRCA1/2 mutation testing pathway initiated in the oncology clinic for patients with HGSEC, either at primary diagnosis or first relapse, whereby only patients with a positive germline BRCA1/2 mutation test will be referred to clinical genetics. Germline BRCA1 and BRCA2 MLPA will be carried out to ensure accurate detection of BRCA1/2 LGRs. Patients with a high clinical risk of being germline mutation carriers and a negative germline BRCA1/2 mutation test should also be referred to clinical genetics. The investigators believe an upfront tumour testing pathway would be more cost-effective, as it would involve testing all patients for tumour BRCA1/2 mutations, followed by a single site germline test to clarify somatic/germline status of this mutation in approximately 25% of patients. In contrast, an upfront germline testing pathway would involve germline BRCA1/2 testing for all patients, followed by tumour BRCA1/2 tests in those 80 - 82% patients who do not have a germline BRCA1/2 mutation.
Systematic testing of patients in the oncology clinic for tumour BRCA1/2 mutations should not only ensure that all patients who are eligible for and agreeable to testing receive it, but also improve the quality of referrals to the clinical genetics team. Moreover, this approach is likely to significantly improve the identification rate of HGSEC patients with germline BRCA1/2 mutations, with resultant benefits for these patients in terms of cancer treatment and prevention, and their families in terms of opportunities for cancer prevention. The identification of patients with BRCA1/2 mutant HGSEC may facilitate treatment with effective maintenance therapies, or participation in clinical trials targeted at patients with BRCA1/2-mutated HGSEC. The incorporation of a health economics analysis relating to the introduction of this proposed testing pathway will further inform on the feasibility of its adoption into routine clinical practice on study completion. Finally, this study will also report on the currently unknown frequency, characteristics, disease course, and treatment patterns of germline and somatic BRCA1/2 mutations in an Irish population with HGSEC.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Leinster
-
Dublin, Leinster, Ireland
- St James's Hospital
-
Dublin, Leinster, Ireland
- Mater Misericordiae University Hospital / Mater Private Hospital
-
-
Munster
-
Cork, Munster, Ireland
- Cork University Hospital
-
Cork, Munster, Ireland
- Bon Secours
-
Limerick, Munster, Ireland
- University Hospital Limerick
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients with high grade serous or high grade endometrioid ovarian, fallopian tube or primary peritoneal carcinoma who:
Are newly diagnosed FIGO stage I - IV or Are currently undergoing primary chemotherapy +/- surgery or Are in remission after completing primary treatment for FIGO stage I - IV disease or Are being planned for, are undergoing or have completed treatment for first relapse
- Patients with available tumour tissue (archival FFPE surgical resection or tissue/peritoneal biopsy) obtained prior to chemotherapy delivery, for tumour BRCA1/2 testing
- Patients able to give signed and written informed consent
- Patients aged 18 years and above
Exclusion Criteria:
- Patients with non-high grade serous or non-high grade endometrioid ovarian, fallopian tube or primary peritoneal carcinoma or unclear histology
- Patients in second or later relapse of their disease
- Patients who are known BRCA1 or BRCA2 mutation carriers
- Patients who have been previously tested for germline BRCA1/2 mutations or have been tested with a hereditary cancer gene panel.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with HGSEC
|
Germline BRCA1/2 mutation testing will be undertaken by NGS using blood samples.
Somatic BRCA1/2 mutation testing will be undertaken by NGS using tumour tissue.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of an upfront BRCA1/2 mutation testing pathway in HGSEC in terms of clinicians' experience.
Time Frame: 24 months
|
The primary outcome measure is to assess the feasibility and potential resource impact of the initiation of an ovarian cancer tumour tissue BRCA1/2 mutation testing pathway in the oncology clinic.
This will be assessed in terms of clinicians' and patients' experience, impact on patient management and health economic analysis is the primary outcome measure.
The primary outcome measure will be assessed via Clinician and patient questionnaires which will evaluate satisfaction/experience with tBRCA testing pathway.
|
24 months
|
Feasibility of an upfront BRCA1/2 mutation testing pathway in HGSEC in terms of patients' experience.
Time Frame: 24 months
|
The feasibility will be assessed via Patient experience questionnaires.
The patient experience questionnaires will evaluate patients' understanding of tBRCA testing, satisfaction/experience with tBRCA testing pathway, and feedback on the tBRCA testing pathway.
|
24 months
|
The impact on patient management by determining changes in patient treatment (use of a PARP inhibitor or enrolment in BRCA-targeted clinical trials).
Time Frame: 24 months
|
A quantifiable outcome measure cannot be added here.
The result of the BRCA testing impacts on the treatment decisions which the clinicians makes for the patient.
|
24 months
|
The impact on patient management by use of clinical genetics counselling sessions.
Time Frame: 24 months
|
24 months
|
|
The economic impact of implementing an upfront tumour BRCA1/2 mutation testing pathway in the oncology clinic for HGSEC on the Irish healthcare system, using a health economic analysis (decision analysis model)
Time Frame: 24 months
|
A decision analysis model will be created to compare the costs and benefits of three BRCA1/2 mutation testing strategies for patients with HGSEC.
Health benefit will be measured in quality adjusted life years (QALYs).
Costs in the model will include genetic counselling, genetic tests, breast cancer screening, risk reducing surgeries (RRS), palliative care and cancer treatment for patients and their first and second-degree relatives.
QALYs will be calculated per individual and aggregated to provide an incremental cost-effectiveness ratio (ICER).
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of germline and somatic BRCA1 and BRCA2 mutations among patients with HGSEC in Ireland
Time Frame: 78 months
|
Descriptive statistics will be calculated to summarize the number of patients with Germline BRCA1/2 mutations, somatic BRCA1/2 mutations and Variants of Unknown Significance (VUS).
Counts, ranges and percentages will be used.
|
78 months
|
Patient and disease characteristics (age, stage, degree of surgical cytoreduction, platinum sensitivity) associated with BRCA1/2 mutated HGSEC compared to BRCA1/2 wild type disease.
Time Frame: 78 months
|
78 months
|
|
Differences in treatment patterns between BRCA1/2 mutated and BRCA1/2 wild type HGSEC by examining number of systemic therapies used.
Time Frame: 78 months
|
78 months
|
|
Differences in treatment patterns between BRCA1/2 mutated and BRCA1/2 wild type HGSEC by examining use of PARP inhibitor therapy.
Time Frame: 78 months
|
78 months
|
|
Differences in treatment patterns between BRCA1/2 mutated and BRCA1/2 wild type HGSEC by examining enrolment in clinical trials
Time Frame: 78 months
|
78 months
|
|
Identification of clinical outcomes (response platinum free interval (PFI)) associated with BRCA1/2-mutated HGSEC, as compared to BRCA1/2 wild type disease.
Time Frame: 78 months
|
78 months
|
|
Identification of clinical outcomes (progression free survival (PFS)) associated with BRCA1/2-mutated HGSEC, as compared to BRCA1/2 wild type disease.
Time Frame: 78 months
|
78 months
|
|
Identification of clinical outcomes (overall survival (OS)) associated with BRCA1/2-mutated HGSEC, as compared to BRCA1/2 wild type disease.
Time Frame: 78 months
|
78 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Prof. Bryan Hennessy, Beaumont Hospital, Ireland
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Uterine Neoplasms
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Fallopian Tube Diseases
- Endometrial Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Carcinoma
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Carcinoma, Endometrioid
Other Study ID Numbers
- CTRIAL-IE 18-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fallopian Tube Cancer
-
OncoMed Pharmaceuticals, Inc.CompletedCancer Ovaries | Cancer Peritoneal | Cancer, Fallopian TubeUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedStage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian... and other conditionsUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...Istituto Di Ricerche Farmacologiche Mario Negri; Foundation MedicineRecruitingAdvanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube CancerItaly
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Active, not recruitingStage I Ovarian Cancer AJCC v6 and v7 | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC v6 and v7 | Stage II Ovarian Cancer AJCC v6 and v7 | Stage IIA Fallopian Tube Cancer AJCC v6 and v7 | Stage IIB Fallopian... and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterGenentech, Inc.CompletedOvarian Cancer | Peritoneal Cancer | Fallopian Tubes CancerUnited States
-
Genentech, Inc.CompletedOvarian Cancer | Fallopian Tube Cancer | Peritoneal CancerUnited States
-
Precision TherapeuticsCompletedOvarian Cancer | Fallopian Tube Cancer | Peritoneal CancerUnited States
-
Centre Jean PerrinCompletedOvarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity CancerFrance
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer | Stage IIA Fallopian Tube Cancer | Stage IIB Fallopian Tube Cancer | Stage IIC Fallopian Tube Cancer | Stage... and other conditions
Clinical Trials on Somatic and Germline BRCA1/2 Testing
-
Lund UniversityCompletedHereditary Breast CancerSweden
-
RWJ Barnabas Health at Jersey City Medical CenterUnknownLynch Syndrome | Endometrial Cancer | Somatic Mutation | Cancer Gene MutationUnited States
-
AGO Research GmbHCompleted
-
Fondazione Policlinico Universitario Agostino Gemelli...Completed
-
The University of Texas Health Science Center at...National Center for Advancing Translational Sciences (NCATS); IIMS-UT Health...RecruitingGastric CancerUnited States
-
Alexandru EniuIuliu Hatieganu University of Medicine and PharmacyCompletedTo Determine the Prevalence, Penetrance of BRCA1 and BRCA2 Mutations in Romanian Womens With Breast or Ovarian CancerRomania
-
Washington University School of MedicineMercy ResearchActive, not recruitingCovid19 | Preterm Birth | Pregnancy Related | Coronavirus | Neonatal Infection | Prenatal Stress | Maternal Complication of PregnancyUnited States
-
Quidel CorporationCompletedBorrelia; Infection, Burgdorferi (Erythema Chronicum Migrans)United States
-
Stony Brook UniversityCompleted
-
Elizabeth Glaser Pediatric AIDS FoundationUNITAID; Kenya Ministry of Health; Ministry of Public Health, CameroonCompleted